Clinical Trial Update: Clinical Investigation of Erlotinib as an HCV Entry Inhibitor [Phase 1, Phase 2]

View source ↗

Summary

A clinical trial update on the investigation of Erlotinib as an entry inhibitor for hepatitis C, spanning Phase 1 and Phase 2.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Tarceva (erlotinib) (erlotinib)

Snippet

Sponsor: University Hospital, Strasbourg, France | Conditions: Chronic Hepatitis C Infection, HCV Genotype 1b | Phase 1, Phase 2 | Status: UNKNOWN